# Amgen 386 for Recurrent Glioblastoma

> **NCT01290263** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 48 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Amgen 386
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01290263
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-07
- **Final completion:** 2017-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01290263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01290263, "Amgen 386 for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01290263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*